EMA Authorised: Tavlesse (Fostamatinib disodium) — Instituto Grifols S.A.

View source ↗

Summary

EMA authorised Tavlesse (fostamatinib disodium) for thrombocytopenia, with Instituto Grifols S.A. as the marketing authorisation holder; decision dated 13 Novem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia
• Thrombocytopenia

Drugs mentioned

• Tavlesse (fostamatinib disodium)

Snippet

Status: Authorised. Therapeutic area: Thrombocytopenia. MAH: Instituto Grifols S.A.. Decision date: 13/11/2024